lorvotuzumab mertansine (IMGN901) / ImmunoGen, AbbVie  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lorvotuzumab mertansine (IMGN901) / AbbVie
IMGN901, NCT00346255: BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Completed
1
37
US, RoW
BB-10901, IMGN901
ImmunoGen, Inc.
Multiple Myeloma
03/11
03/11
NCT00346385: BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Completed
1
97
US, Europe
BB-10901, IMGN901
ImmunoGen, Inc.
Ovarian Cancer, Merkel Cell Carcinoma, SCLC
10/11
10/11
NCT00991562: IMGN901 in Combination With Lenalidomide and Dexamethasone

Checkmark P1 data: ASH (MM)
Dec 2012 - Dec 2012: P1 data: ASH (MM)
Completed
1
50
US
IMGN901, BB-10901, huN901-DM1
ImmunoGen, Inc.
Multiple Myeloma
08/13
10/14

Download Options